Revolution Medicines (RVMD) Accumulated Expenses (2019 - 2026)

Revolution Medicines' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $5.0 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 62.81% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $5.0 million (down 62.81% YoY), while the FY2025 annual figure was $209.3 million, up 116.67% from the prior year.
• Accumulated Expenses was $5.0 million for Q1 2026 at Revolution Medicines, down from $209.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $256.5 million in Q3 2025 to a low of $5.0 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $65.8 million across 5 years, with a median of $42.6 million in 2023.
• Biggest YoY gain for Accumulated Expenses was 549.92% in 2023; the steepest drop was 77.11% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $29.4 million in 2022, then surged by 153.66% to $74.7 million in 2023, then grew by 29.35% to $96.6 million in 2024, then jumped by 116.67% to $209.3 million in 2025, then sank by 97.61% to $5.0 million in 2026.
• The last three Accumulated Expenses figures came in at $5.0 million (Q1 2026), $209.3 million (Q4 2025), and $256.5 million (Q3 2025), per Business Quant data.